Showing results (61-70 of 67) with videos related to
Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Blood Advances|September 21, 2021
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignanciesMatthew S Davids, Owen A O'Connor, Wojciech Jurczak, et al.Haematologica|October 4, 2024
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trialNirav N Shah, Michael Wang, Lindsey E Roeker, et al.The Lancet. Haematology|July 21, 2024
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN studyWilliam G Wierda, Nirav N Shah, Chan Y Cheah, et al.The New England Journal of Medicine|July 5, 2023
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic LeukemiaAnthony R Mato, Jennifer A Woyach, Jennifer R Brown, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2023
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell LymphomaMichael L Wang, Wojciech Jurczak, Pier Luigi Zinzani, et al.The Lancet. Haematology|May 2, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trialM Lia Palomba, Manish R Patel, Toby A Eyre, et al.Lancet (London, England)|March 7, 2021
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R Mato, Nirav N Shah, Wojciech Jurczak, et al.Pageof 7